Nazarov 2003.

Methods	Parallel‐group RCT
Participants	116 participants with moderate to severe perennial allergic conjunctivitis
Interventions	Two treatment arms: azelastine 0.015 mg; placebo. Duration of treatment 6 weeks
Outcomes	Participants' and clinicians' assessment of ocular symptoms (sum score itching and redness, using a 4‐point scale; 0 = none, 3 = severe) Time points: at baseline and day 7, 21, and 42 of treatment
Country	Germany
Number randomised, gender (male:female)	116 participants randomised and analysed. M:F 26:90
Age mean (SD), median, range	Mean (range): azelastine 35.7 years (17‐63); placebo 31.7 years (17‐59)
Notes	Study conducted from 19 December 1998 to 14 April 1999. Source of funding not stated. Declaration of interest by the authors was not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The method used to generate the allocation sequence was not described
Allocation concealment (selection bias)	Unclear risk	The method used to conceal the allocation sequence was not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data were nearly fully reported, with less than 10% lost to follow‐up, and reasons were given
Selective reporting (reporting bias)	Low risk	Evidence was available of proper outcome reporting
Other bias	Low risk	No apparent evidence of other risk of bias
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐masked (p.169 ‐ patients, materials and methods): "The investigation was conducted as a double‐blind, randomised..." Both drugs with identical packaging (p.169 ‐ treatment): "Both azelastine eye drops and the matching vehicle containing placebo were provided by ASTA Medica AG in identical packaging."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐masked (p.169 ‐ patients, materials and methods): "The investigation was conducted as a double‐blind, randomised..." Both drugs with identical packaging (p.169 ‐ treatment): "Both azelastine eye drops and the matching vehicle containing placebo were provided by ASTA Medica AG in identical packaging."